Cargando…
Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive neurodegenerative disease, and only modest disease-modifying strategies have been established to date. Numerous clinical trials have been conducted in the past years, but have been severely hampered by the wide-ranging heterogeneity o...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921583/ https://www.ncbi.nlm.nih.gov/pubmed/35105727 http://dx.doi.org/10.1136/jnnp-2021-327503 |
_version_ | 1784669354489544704 |
---|---|
author | Dreger, Marie Steinbach, Robert Otto, Markus Turner, Martin R Grosskreutz, Julian |
author_facet | Dreger, Marie Steinbach, Robert Otto, Markus Turner, Martin R Grosskreutz, Julian |
author_sort | Dreger, Marie |
collection | PubMed |
description | Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive neurodegenerative disease, and only modest disease-modifying strategies have been established to date. Numerous clinical trials have been conducted in the past years, but have been severely hampered by the wide-ranging heterogeneity of both the biological origins and clinical characteristics of the disease. Thus, reliable biomarkers of disease activity are urgently needed to stratify patients into homogenous groups with aligned disease trajectories to allow a more effective design of clinical trial. In this review, the most promising candidate biomarkers in the cerebrospinal fluid (CSF) of patients with ALS will be summarised. Correlations between biomarker levels and clinical outcome parameters are discussed, while highlighting potential pitfalls and intercorrelations of these clinical parameters. Several CSF molecules have shown potential as biomarkers of progression and prognosis, but large, international, multicentric and longitudinal studies are crucial for validation. A more standardised choice of clinical endpoints in these studies, as well as the application of individualised models of clinical progression, would allow the quantification of disease trajectories, thereby allowing a more accurate analysis of the clinical implications of candidate biomarkers. Additionally, a comparative analysis of several biomarkers and ideally the application of a multivariate analysis including comprehensive genotypic, phenotypic and clinical characteristics collectively contributing to biomarker levels in the CSF, could promote their verification. Thus, reliable prognostic markers and markers of disease activity may improve clinical trial design and patient management in the direction of precision medicine. |
format | Online Article Text |
id | pubmed-8921583 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-89215832022-03-25 Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis Dreger, Marie Steinbach, Robert Otto, Markus Turner, Martin R Grosskreutz, Julian J Neurol Neurosurg Psychiatry Neuromuscular Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive neurodegenerative disease, and only modest disease-modifying strategies have been established to date. Numerous clinical trials have been conducted in the past years, but have been severely hampered by the wide-ranging heterogeneity of both the biological origins and clinical characteristics of the disease. Thus, reliable biomarkers of disease activity are urgently needed to stratify patients into homogenous groups with aligned disease trajectories to allow a more effective design of clinical trial. In this review, the most promising candidate biomarkers in the cerebrospinal fluid (CSF) of patients with ALS will be summarised. Correlations between biomarker levels and clinical outcome parameters are discussed, while highlighting potential pitfalls and intercorrelations of these clinical parameters. Several CSF molecules have shown potential as biomarkers of progression and prognosis, but large, international, multicentric and longitudinal studies are crucial for validation. A more standardised choice of clinical endpoints in these studies, as well as the application of individualised models of clinical progression, would allow the quantification of disease trajectories, thereby allowing a more accurate analysis of the clinical implications of candidate biomarkers. Additionally, a comparative analysis of several biomarkers and ideally the application of a multivariate analysis including comprehensive genotypic, phenotypic and clinical characteristics collectively contributing to biomarker levels in the CSF, could promote their verification. Thus, reliable prognostic markers and markers of disease activity may improve clinical trial design and patient management in the direction of precision medicine. BMJ Publishing Group 2022-04 2022-02-01 /pmc/articles/PMC8921583/ /pubmed/35105727 http://dx.doi.org/10.1136/jnnp-2021-327503 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Neuromuscular Dreger, Marie Steinbach, Robert Otto, Markus Turner, Martin R Grosskreutz, Julian Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis |
title | Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis |
title_full | Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis |
title_fullStr | Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis |
title_full_unstemmed | Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis |
title_short | Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis |
title_sort | cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis |
topic | Neuromuscular |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921583/ https://www.ncbi.nlm.nih.gov/pubmed/35105727 http://dx.doi.org/10.1136/jnnp-2021-327503 |
work_keys_str_mv | AT dregermarie cerebrospinalfluidbiomarkersofdiseaseactivityandprogressioninamyotrophiclateralsclerosis AT steinbachrobert cerebrospinalfluidbiomarkersofdiseaseactivityandprogressioninamyotrophiclateralsclerosis AT ottomarkus cerebrospinalfluidbiomarkersofdiseaseactivityandprogressioninamyotrophiclateralsclerosis AT turnermartinr cerebrospinalfluidbiomarkersofdiseaseactivityandprogressioninamyotrophiclateralsclerosis AT grosskreutzjulian cerebrospinalfluidbiomarkersofdiseaseactivityandprogressioninamyotrophiclateralsclerosis |